PLoS ONE · 2010 · 145 citations · 28 references
MedicineMolecular BiologyOncologyGene ExpressionSignal TransductionTranscriptional RegulationCancer Cell SignalingGrowth Factor SignalingOncogenic Signaling PathwaysSignal Transduction In CancerTherapeutic ResistanceTyrosine Kinase InhibitorsEgfr DependenceEgfr InhibitionExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingLuciferase Reporter AssaysLuciferase ReportersResistance To Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitor Therapy
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance and relapse. Gene expression analysis of NSCLC cell lines treated with the EGFR TKI, gefitinib, revealed increased levels of FGFR2 and FGFR3 mRNA. Analysis of gefitinib action on a larger panel of NSCLC cell lines verified that FGFR2 and FGFR3 expression is increased at the mRNA and protein level in NSCLC cell lines in which the EGFR is dominant for growth signaling, but not in cell lines where EGFR signaling is absent. A luciferase reporter containing 2.5 kilobases of fgfr2 5' flanking sequence was activated after gefitinib treatment, indicating transcriptional regulation as a contributing mechanism controlling increased FGFR2 expression. Induction of FGFR2 and FGFR3 protein as well as fgfr2-luc activity was also observed with Erbitux, an EGFR-specific monoclonal antibody. Moreover, inhibitors of c-Src and MEK stimulated fgfr2-luc activity to a similar degree as gefitinib, suggesting that these pathways may mediate EGFR-dependent repression of FGFR2 and FGFR3. Importantly, our studies demonstrate that EGFR TKI-induced FGFR2 and FGFR3 are capable of mediating FGF2 and FGF7 stimulated ERK activation as well as FGF-stimulated transformed growth in the setting of EGFR TKIs. In conclusion, this study highlights EGFR TKI-induced FGFR2 and FGFR3 signaling as a novel and rapid mechanism of acquired resistance to EGFR TKIs and suggests that treatment of NSCLC patients with combinations of EGFR and FGFR specific TKIs may be a strategy to enhance efficacy of single EGFR inhibitors.
28
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Clonogenic assay of cells in vitro
Nicolaas A.P. Franken, Hans M. Rodermond, Jan Stap et al. · Nature Protocols · 2006 · 4.2K citations
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma, Diana Lee, Bihua Li et al. · Cell · 2010 · 2.8K citations · Full text
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova, Ailan Guo, Qingfu Zeng et al. · Cell · 2007 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +16